Sanofi #39;s first-half profit rises 21 PARIS Sanofi-Synthlabo, which this month completed its \$63 billion purchase of a rival drug manufacturer, Aventis, reported Tuesday a 21 percent jump in first-half profit on higher demand for the blood thinner Plavix and the cancer treatment Eloxatin.